Merck And Co Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Merck And Co Inc in the second quarter 2026?
Merck and Co Inc achieved a return on average equity (ROE) of 6.59 % in its second quarter 2026, which is below Merck And Co Inc 's average return on equity, which stands at 21.59%.

ROE fell compared to the first quarter 2026, despite the net income growth of % from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 57 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 756 to 757.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-14.42 %	-5.1 %	13.56 %	16.49 %	-
Y / Y Net Income Change	-	-	-20.86 %	83.07 %	-18.92 %
Net Income (TTM) in Millions	3,170	8,935	18,263	19,044	16,418
Return On Equity (TTM)	6.59 %	17.91 %	36.16 %	38.92 %	34.86 %
MRK's Total Ranking	# 757	# 756	# 245	# 217	# 247
Equity (TTM) in Millions	41,984	45,931	52,662	51,907	49,060
Seq. Equity Change	-8.59 %	-12.78 %	1.45 %	5.8 %	1.36 %
Seq. Net Income Change	-	-	-48.8 %	30.69 %	-12.92 %

Back to MRK Management Effectiveness >> MRK's 5 Years Annual ROE >> Compare MRK ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 58
Sector	# 161
Overall	# 757

Return On Equity Statistics
High	Average	Low
42.75 %	21.59 %	0.92 %
(Dec. 30, 2009)		(Dec 31 2023)

MRK Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	52,662	46,372	37,635	46,058	38,257
Y / Y Equity Change	13.56 %	23.22 %	-18.29 %	20.39 %	50.59 %
Net Income in Millions	18,263	17,133	377	14,526	13,062
Y / Y Net Income Change	6.6 %	4444.56 %	-97.4 %	11.21 %	84.44 %
Return On Equity	34.68 %	36.95 %	1 %	31.54 %	34.14 %

Back to MRK Management Effectiveness >> MRK's 5 Years Annual ROE >> Compare MRK ROE to its Competitors

Annual Roe Comment

In 2025 ROE fell to 34.68 %, despite net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MRK's' Return on Equity at Yahoo Finance
MRK's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MRK's Competitors
Subscribers only: Roe for Merck And Co Inc 's Suppliers
Subscribers only: Return On Equity for MRK's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Intuitive Surgical Inc	17.82 %
Standard Biotools Inc	17.64 %
Inspire Medical Systems inc	17.62 %
Medinotec Inc	17.47 %
Lemaitre Vascular Inc	16.93 %
Ufp Technologies Inc	16.72 %
Ensign Group Inc	16.53 %
Stryker Corp	16.36 %
Nephros Inc	16.20 %
Spero Therapeutics Inc	16.17 %
Progyny Inc	15.98 %
Collegium Pharmaceutical Inc	15.96 %
Alpha Pro Tech Ltd	15.43 %
Livanova Plc	15.41 %
Biolife Solutions Inc	15.28 %
Lifevantage Corp	15.06 %
Quest Diagnostics Inc	14.85 %
Infusystem Holdings Inc	14.81 %
Boston Scientific Corporation	14.77 %
Strata Critical Medical Inc	14.27 %
Beone Medicines Ltd	14.24 %
Royalty Pharma Plc	13.82 %
Regeneron Pharmaceuticals Inc	13.81 %
National Healthcare Corp	13.11 %
Kewaunee Scientific Corporation	12.61 %
Protagonist Therapeutics inc	11.80 %
Entrada Therapeutics Inc	11.77 %
Haemonetics Corporation	11.66 %
Globus Medical Inc	11.59 %
Labcorp Holdings Inc	11.58 %

Date modified: 2026-09-12T06:19:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.